In short
Zimmer Biomet Holdings, Inc. (ZBH) has revenue up 7.2% to $8.2B and net income down 22.0% to $705.1M year on year. Its net margin is 8.6%, and it trades at 21.6× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this
Compare: MDT vs ZBH · ABT vs ZBH · BSX vs ZBH · SYK vs ZBH
Valuation
HealthcareLive · Yahoo FinancePrice
$98.58
$18.8B
10.0x
1.01%
52-Week Range
Decision Context
Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.
Based on filing period ending Jun 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.75%
Accommodative
10-Year Treasury
4.99%
2026-09-01
Unemployment
4.2%
Near full employment
CPI Index
334.1
2026-08-01
M2 Money Supply
$23.3T
2026-08-01
The Federal Funds rate stands at 3.75% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.99%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 103.1; M2 money supply is $23.3T; CPI index stands at 334.1.
SWOT Analysis — ZBH
Inflationary BoomStrengths
Operating Cash Flow: $1.7B (+13.2% YoY) — Operating cash flow grew 13% — the business generated more cash from day-to-day operations.
Total Assets: $23.1B (+8.1% YoY) — Total assets grew 8% — the company's resource base expanded.
Revenue: $8.2B (+7.2% YoY) — Revenue grew 7% — the company sold more goods or services than the prior year.
Weaknesses
Net Income: $705.1M (-22.0% YoY) — Profit fell 22% but remained positive.
EPS (Diluted): $3.55 (-19.9% YoY) — Earnings per share fell 20%.
Opportunities
No clear opportunities identified at this time.
Threats
No significant threats flagged.
Year-over-Year Changes
Net Income
$705.1M
was $903.8M
Profit fell 22% but remained positive.
EPS (Diluted)
$3.55
was $4.43
Earnings per share fell 20%.
Operating Cash Flow
$1.7B
was $1.5B
Operating cash flow grew 13% — the business generated more cash from day-to-day operations.
Total Assets
$23.1B
was $21.4B
Total assets grew 8% — the company's resource base expanded.
Revenue
$8.2B
was $7.7B
Revenue grew 7% — the company sold more goods or services than the prior year.
Technical Signals
Daily closes · 1-year dataZimmer Biomet Holdings, Inc.: common questions
Is Zimmer Biomet Holdings, Inc. profitable?
Yes. Zimmer Biomet Holdings, Inc. made a net profit of $705M in its latest fiscal year (fiscal 2025), a net margin of 8.6%.
Is Zimmer Biomet Holdings, Inc.'s revenue growing?
Yes. Revenue grew 7.2% year on year, to $8.2B.
What is Zimmer Biomet Holdings, Inc.'s P/E ratio?
Zimmer Biomet Holdings, Inc. trades at 23.9× its trailing twelve-month earnings. In other words, the share price is about 24 times the profit per share the company earned over the past year.
Does Zimmer Biomet Holdings, Inc. pay a dividend?
Yes. Zimmer Biomet Holdings, Inc.'s forward dividend yield is 1.01%, the expected annual dividend as a share of the current share price.
Answers are generated from the figures in this report (updated 9 Oct 2026). Information, not investment advice.
Latest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade ZBH
Links open broker research pages. Not an endorsement or recommendation.
Research Zimmer Biomet Holdings, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.